Center-Authored Papers

Filters: Author is Hendrix, Craig W  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Lu Y, Celum C, Wald A, Baeten JM, Cowan F, Delany-Moretlwe S, Reid SE, Hughes JP, Wilcox E, Corey L et al..  2012.  Acyclovir achieves lower concentration in African HIV-seronegative, HSV-2 seropositive women compared to non-African populations.. Antimicrobial agents and chemotherapy. 56(5):2777-9. Abstract
Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, Nakabiito C, Hoesley C, Justman J, Soto-Torres L et al..  2013.  Adherence and Acceptability in MTN 001: A Randomized Cross-Over Trial of Daily Oral and Topical Tenofovir for HIV Prevention in Women.. AIDS and behavior. 17(2):737-747. Abstract
Herold BC, Dezzutti CS, Richardson BA, Marrazzo J, Mesquita PMM, Carpenter C, Huber A, Louissaint N, Marzinke MA, Hillier SL et al..  2014.  Antiviral Activity of Genital Tract Secretions following Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1.. Journal of acquired immune deficiency syndromes (1999). Abstract
C
Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL et al..  2017.  Characterization of HIV seroconverters in a TDF/FTC PrEP study: HPTN 067/ADAPT.. Journal of acquired immune deficiency syndromes (1999). Abstract
D
Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM.  2014.  Daily Oral Tenofovir and Emtricitabine-Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1-Uninfected Men and Women: A Subgroup Analysis of a Randomized Trial.. Annals of internal medicine. 161(1):11-9. Abstract
Noguchi LM, Montgomery ET, Biggio JR, Hendrix CW, Bogen DL, Hillier SL, Dai JY, Piper JM, Marzinke MA, Dezzutti CS et al..  2016.  Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir.. Antimicrobial agents and chemotherapy. 60(9):5616-5619. Abstract
van der Straten A, Brown ER, Marrazzo JM, Chirenje MZ, Liu K, Gomez K, Marzinke MA, Piper JM, Hendrix CW.  2016.  Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.. Journal of the International AIDS Society. 19(1):20642. Abstract
Hendrix CW, Andrade A, Bumpus NN, Kashuba A, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I et al..  2015.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine after Directly Observed Dosing in Healthy Volunteers to establish Adherence Benchmarks (HPTN 066).. AIDS research and human retroviruses. Abstract
E
Zhang Y, Clarke W, Marzinke MA, Piwowar-Manning E, Beauchamp G, Breaud A, Hendrix CW, Cloherty GA, Emel L, Rose S et al..  2017.  Evaluation of a multi-drug assay for monitoring adherence to a regimen for HIV pre-exposure prophylaxis in a clinical study (HIV Prevention Trials Network 073).. Antimicrobial agents and chemotherapy. Abstract
H
Carballo-Diéguez A, Balán IC, Brown W, Giguere R, Dolezal C, Leu C-S, Marzinke MA, Hendrix CW, Piper JM, Richardson BA et al..  2017.  High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.. PloS one. 12(7):e0181607. Abstract
L
Murphy K, Richardson BA, Dezzutti CS, Marrazzo J, Hillier SL, Hendrix CW, Herold BC.  2015.  Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women.. American journal of reproductive immunology (New York, N.Y. : 1989). Abstract
M
Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM et al..  2013.  MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments.. PloS one. 8(1):e55013. Abstract
Cranston RD, Lama JR, Richardson BA, Carballo-Diéguez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu C-S, Galaska B, Jacobson CE et al..  2016.  MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Abstract
P
Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, Louissaint N, Kalyoussef S, Torres MN, Hladik F, Parikh U et al..  2011.  Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators.. PloS one. 6(8):e23136. Abstract
Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, Chen J, Hendrix CW, Masse B, Valentine M, Piper J et al..  2011.  Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.. The Journal of infectious diseases. 204(10):1527-31. Abstract
Dai JY, Hendrix CW, Richardson BA, Kelly C, Marzinke M, Chirenje MZ, Marrazzo JM, Brown ER.  2016.  Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.. The Journal of infectious diseases. 213(3):335-342. Abstract
Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN et al..  2015.  A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.. AIDS (London, England). Abstract
Chen BA, Panther L, Marzinke MA, Hendrix CW, Hoesley CJ, van der Straten A, Husnik MJ, Soto-Torres L, Nel A, Johnson S et al..  2015.  Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.. Journal of acquired immune deficiency syndromes (1999). 70(3):242-9. Abstract
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico RK, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH et al..  2016.  PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305).. The Journal of infectious diseases. Abstract
Weis JF, Baeten JM, McCoy CO, Warth C, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Mugo N, Iv FMA et al..  2016.  Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.. AIDS (London, England). 30(1):31-5. Abstract
R
Beigi RH, Noguchi LM, Montgomery E, Biggio J, Hendrix CW, Marzinke MA, Dai JY, Pan J, Ayudhya RKN, Schwartz JL et al..  2016.  A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.. Journal of the International AIDS Society. 19(1):20990. Abstract
Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA et al..  2015.  Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.. The Journal of infectious diseases. 211(8):1211-8. Abstract
S
Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico RK, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH et al..  2017.  Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.. Annals of internal medicine. :1-10. Abstract
T
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L et al..  2015.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.. The New England journal of medicine. 372(6):509-18. Abstract
U
Fogel JM, Wang L, Parsons TL, Ou S-S, Piwowar-Manning E, Chen Y, Mudhune VO, Hosseinipour MC, Kumwenda J, Hakim JG et al..  2013.  Undisclosed antiretroviral drug use in a multi-national clinical trial (HPTN 052).. The Journal of infectious diseases. 208(10):1624-8. Abstract